New Barr exec
This article was originally published in The Tan Sheet
Executive Summary
G. Frederick Wilkinson will join Barr in the new position of President and COO of Duramed Pharmaceuticals effective in March, the firm announces Jan. 10. Wilkinson is not a replacement for Duramed Research President Carole Ben-Maimon, who announced her resignation in December (1"The Tan Sheet" Jan, 2, 2006, p. 9). Nonetheless, Wilkinson will manage all aspects of the firm's proprietary products subsidiary, which encompasses the emergency contraceptive Plan B. Growth of the proprietary products business over the last five years to $400 mil. in sales makes it "appropriate to have a management structure dedicated to these operations," according to Barr Chairman and COO Bruce Downey. Wilkinson previously served as CEO of Columbia Labs...
You may also be interested in...
Barr’s Duramed President Ben-Maimon Plans Departure
Barr will start searching for a successor for Carole Ben-Maimon, MD, President and COO of its Duramed Research subsidiary, as soon as possible, the firm announced Dec. 19
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.